Sold as Xenoview. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Xenon Xe-129 Hyperpolarized (sold as Xenoview), first approved Dec 23, 2022, with 1 new use approved and 1 published complete response letter.
| Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation ImagingChronic Obstructive Pulmonary Disease · Polarean, Inc. | Phase 1 | Active, not recruiting | Feb 21, 2024 |
| 129Xe MRI CardiopulmonaryInterstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension · Bastiaan Driehuys | Phase 2 | Recruiting | Sep 15, 2023 |
| Hyperpolarized 129Xe MRI Lung Health CohortHealthy · University of Kansas Medical Center | — | Recruiting | Mar 13, 2023 |
| Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary DiseaseAsthma, COPD · Mario Castro, MD, MPH | Phase 1 | Recruiting | Nov 10, 2020 |
| Letter | Product | Now |
|---|---|---|
| Oct 5, 2021 | Xenoview (xenon-129 hyperpolarized)Product Quality, Facility Inspections | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
